<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167596</url>
  </required_header>
  <id_info>
    <org_study_id>05008</org_study_id>
    <nct_id>NCT00167596</nct_id>
  </id_info>
  <brief_title>Near Infrared Spectroscopy (NIRS) in Severe Sepsis</brief_title>
  <acronym>OTO-STS</acronym>
  <official_title>Phase III Study of Usefulness of Near Infrared Spectroscopy to Optimize Tissues Perfusion and Oxygenation in Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Versailles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hutchinson Technology Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Versailles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the usefulness of an optimization of muscle
      perfusion and oxygenation, as assessed by the NIRS technique, in critically ill patients with
      sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The systemic inflammatory response to sepsis may cause impaired tissue oxygenation that can
      persist despite the restoration of a normal hemodynamic profile and systemic oxygen
      transport.

      Therefore, the assessment of tissue oxygenation and perfusion is recommended in patients with
      severe sepsis.

      The InSpectra tissue spectrometer relies on continuous wave near infrared (NIR) technology to
      estimate non invasively local tissue hemoglobin oxygen saturation in tissue (% StO2). This
      technology had been tested in a variety of systems: standard theoretical models of light
      transport, isolated blood, isolated blood-perfused animal organs and healthy human volunteers
      with induced limb ischemia. In critical-care medicine, NIRS has also been used to evaluate
      muscle oxygenation in trauma resuscitation and in lower extremity and abdominal compartment
      syndrome. However, NIRS has been rarely utilised to measure tissue blood flow and oxygen
      uptake in critically ill patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment was stopped as consequence of cessation of funding (economic crisis)
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A combined endpoint of mortality and sequential organ failure assessment (SOFA) score increase at day 7 is the primary efficacy endpoint</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>from randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of the hospital stay</measure>
    <time_frame>from randomization to Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Critical Illness</condition>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early goal directed therapy based on StO2 evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early goal directed therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near Infrared Spectroscopy</intervention_name>
    <description>resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional</intervention_name>
    <description>resuscitation will be based according to Surviving Sepsis Campaign</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two of four criteria for the systemic inflammatory response syndrome; and one of the
             following:

               -  systolic blood pressure =&lt; 90 mm Hg; or

               -  a blood lactate concentration =&gt; 4 mmol/l; or

               -  skin marbling; or

               -  impaired consciousness; or

               -  urine output &lt; 30 ml/h.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnancy

          -  Do-not-resuscitate status

          -  Advanced directives restricting implementation of the protocol

          -  Obesity (body mass index [BMI] &gt; 30)

          -  Anasarca
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali Annane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Raymond Poincaré Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Nardi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Raymond Poincaré Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwenhael Colin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raymond Poincaré Hospital, AP-HP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Raymond Poincaré Hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord AP HM</name>
      <address>
        <city>Marseilles</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GERLACH Herwig</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NANAS Serafeim</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EZAVALA Elizabeth</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Versailles</investigator_affiliation>
    <investigator_full_name>Djillali Annane</investigator_full_name>
    <investigator_title>Professor in medicine</investigator_title>
  </responsible_party>
  <keyword>near infrared spectroscopy</keyword>
  <keyword>tissue oxygenation</keyword>
  <keyword>organ dysfunction</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

